Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer

June 23, 2022 | Hope Rugo, MD, FASCO

Share on:
View More
Current Time 0:00
Duration 15:34
Loaded: 0%
Stream Type LIVE
Remaining Time 15:34
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected
View More
TROPiCS_RRO_Rugo_Seg01_Slides
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

        Hope Rugo, MD, FASCO, reviews safety and efficacy results from the TROPiCS-02 trial and discusses the clinical implications of the data.